<DOC>
	<DOCNO>NCT00500656</DOCNO>
	<brief_summary>Primary Outcome Measures : The primary endpoint time onset symptom relief first attack double blind phase . H0 : λ icatibant/λ tranexamic acid =1 versus H1 : λ icatibant/λ tranexamic acid ≠1 Where : λ icatibant refers hazard rate icatibant λ tranexamic acid refers hazard rate tranexamic acid . Secondary Outcome Measures : - Additional efficacy assessment ( Time Almost Complete Symptom Relief ) - Safety tolerability - Pharmacoeconomics</brief_summary>
	<brief_title>Subcutaneous Treatment With Icatibant Acute Attacks Hereditary Angioedema ( HAE )</brief_title>
	<detailed_description>This Phase III , randomise , double blind , double dummy , multicentre , control , parallel group study 30 mg s.c. formulation icatibant treatment patient moderate severe symptom cutaneous and/or abdominal symptom HAE . The study consist two part : control phase OLE phase . For primary endpoint , Efficacy determine evaluate difference study outcome use Visual Analogue Scale patient treat icatibant tranexamic acid .</detailed_description>
	<mesh_term>Angioedema</mesh_term>
	<mesh_term>Angioedemas , Hereditary</mesh_term>
	<mesh_term>Icatibant</mesh_term>
	<mesh_term>Bradykinin</mesh_term>
	<mesh_term>Tranexamic Acid</mesh_term>
	<criteria>Age 18 year ; Documented diagnosis HAE Type I II ( confirm C1INH deficiency ) ; Current edema cutaneous , abdominal and/or laryngeal area ; Current edema moderate severe accord investigator 's Symptom Score . Diagnosis angioedema HAE , Participation clinical trial another investigational medicinal product ( IMP ) within past month Treatment pain medication since onset current angioedema attack Treatment replacement therapy , include C1INH product , less 3 day onset current angioedema attack Treatment Tranexamic acid replacement therapy within week onset current angioedema attack Treatment ACE inhibitor Contraindications Tranexamic acid Evidence coronary artery disease base medical history Screening examination particular unstable angina pectoris severe coronary heart disease Congestive heart failure ( class 3 4 ) Serum creatinine level ≥ 250 μmol/L Serious concomitant illness investigator consider contraindication participation trial Pregnancy ( assessed prior treatment ) and/or breastfeed</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2014</verification_date>
</DOC>